Shares of this drugmaker are soaring on Monday after the company reported positive topline results from the pivotal Phase 3 clinical trial of resmetirom, a liver-directed selective thyroid hormone receptor agonist. The news that… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3635228/-Trial-success-is-rocketing-this-NASH-stock-higher-and-sinking-these-peers)
previous post